Empowering Graph Neural Network-Based Computational Drug Repositioning with Large Language Model-Inferred Knowledge Representation
- 26 September 2024
- journal article
- research article
- Published by Springer Nature in Interdisciplinary Sciences: Computational Life Sciences
- Vol. 17 (3) , 698-715
Abstract
Computational drug repositioning, through predicting drug-disease associations (DDA), offers significant potential for discovering new drug indications. Current methods incorporate graph neural networks (GNN) on drug-disease heterogeneous networks to predict DDAs, achieving notable performances compared to traditional machine learning and matrix factorization approaches. However, these methods depend heavily on network topology, hampered by incomplete and noisy network data, and overlook the wealth of biomedical knowledge available. Correspondingly, large language models (LLMs) excel in graph search and relational reasoning, which can possibly enhance the integration of comprehensive biomedical knowledge into drug and disease profiles. In this study, we first investigate the contribution of LLM-inferred knowledge representation in drug repositioning and DDA prediction. A zero-shot prompting template was designed for LLM to extract high-quality knowledge descriptions for drug and disease entities, followed by embedding generation from language models to transform the discrete text to continual numerical representation. Then, we proposed LLM-DDA with three different model architectures (LLM-DDANode Feat, LLM-DDADual GNN, LLM-DDAGNN-AE) to investigate the best fusion mode for LLM-based embeddings. Extensive experiments on four DDA benchmarks show that, LLM-DDAGNN-AE achieved the optimal performance compared to 11 baselines with the overall relative improvement in AUPR of 23.22%, F1-Score of 17.20%, and precision of 25.35%. Meanwhile, selected case studies of involving Prednisone and Allergic Rhinitis highlighted the model’s capability to identify reliable DDAs and knowledge descriptions, supported by existing literature. This study showcases the utility of LLMs in drug repositioning with its generality and applicability in other biomedical relation prediction tasks. Graphical abstractKeywords
This publication has 57 references indexed in Scilit:
- Estimation of clinical trial success rates and related parametersBiostatistics, 2018
- Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After ApprovalJAMA Internal Medicine, 2017
- Drug repositioning based on comprehensive similarity measures and Bi-Random walk algorithmBioinformatics, 2016
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016
- A survey of current trends in computational drug repositioningBriefings in Bioinformatics, 2015
- DrugNet: Network-based drug–disease prioritization by integrating heterogeneous dataArtificial Intelligence in Medicine, 2015
- Recent Advances in Drug Repositioning for the Discovery of New Anticancer DrugsInternational Journal of Biological Sciences, 2014
- Computational Drug Repositioning: From Data to TherapeuticsClinical Pharmacology & Therapeutics, 2013
- PREDICT: a method for inferring novel drug indications with application to personalized medicineMolecular Systems Biology, 2011
- Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo‐controlled environmental trialActa Ophthalmologica, 2009